Supriya Lifescience Ltd - pure play API

+4.4

Market Impact Score

-100 Bearish+100 Bullish

AI Analysis

The Indian pharmaceutical sector, particularly the API segment, is crucial for global drug supply chains. Regulatory changes and pricing pressures significantly influence profitability and growth.

Trading Insight

Monitor API manufacturers for signs of increased export orders or new product approvals, indicating potential upside, while being mindful of raw material cost fluctuations.

Quick check: SUPRIYA neutral, DIVISLAB bearish bias (+0.1% 1d).

Key Evidence

•Supriya Lifescience Ltd. (SLL) is a manufacturer and supplier of active pharmaceuticals ingredients (APIs).
•The company was founded by Satish Wagh and converted to a limited company in 2008.
•SLL has its main plant at Lote and exports APIs globally.
•Key Indian competitors include Divi’s Laboratories, Wanbury, Unichem, Mangalam Drugs, IPCA, and Teva API.
•SLL operates a facility with 547 KL/day reactor capacity and a DSIR approved R&D facility.

Affected Stocks

SUPRIYASupriya Lifescience Ltd.

Mixed

The article provides an introduction to the company without new financial data or events, serving as a profile.

DIVISLABDivi's Laboratories Ltd.

Mixed